🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. JBT-101

    Corbus Pharmaceuticals Holdings

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule terminated

    1 trial

  2. JBT-101

    Corbus Pharmaceuticals Holdings

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  3. JBT-101

    Corbus Pharmaceuticals Holdings

    Dermatomyositis

    phase 2 small molecule terminated

    1 trial

  4. JBT-101 (lenabasum)

    Corbus Pharmaceuticals Holdings

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  5. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  6. JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  7. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  8. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  9. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

  10. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Excessive Sleepiness

    phase 2 small molecule completed

    1 trial

  11. JZP150

    Jazz Pharmaceuticals Ireland Limited

    Post Traumatic Stress Disorder

    phase 2 small molecule completed

    1 trial

  12. JZP3507

    Jazz Pharmaceuticals Ireland Limited

    Meningioma

    phase 2 small molecule active

    1 trial

  13. JZP385

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  14. JZP541

    Jazz Pharmaceuticals Ireland Limited

    Irritability Associated With Autism Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  15. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 small molecule active

    1 trial

  16. JZP598, TRASTUZUMAB EMTANSINE, DOCETAXEL , TRASTUZUMAB , PACLITAXEL , PACLITAXEL ALBUMIN-BOUND, PERTUZUMAB , CARBOPLATIN , TRASTUZUMAB EMTANSINE

    Jazz Pharmaceuticals Ireland Limited

    HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  17. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  18. KAE609

    Novartis Pharmaceuticals

    Cure Rate

    phase 2 small molecule completed

    1 trial

  19. KAE609

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  20. KAF156

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  21. KAF156

    Novartis Pharmaceuticals

    Acute Uncomplicated Plasmodium Falciparum Malaria

    phase 2 small molecule completed

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, evorpacept

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources